Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. That is the WHO definition, and the key word is adequate — adequate meaning the right organism, at the right dose, in a formulation that survives the journey to the gut, for a condition where there is actual evidence of benefit. Most probiotic supplements on the market meet some of these criteria some of the time. Very few meet all of them reliably, and almost none are chosen based on evidence that the specific strain they contain is appropriate for the specific condition the person is trying to address.
The central problem with probiotic recommendations — including most that come from otherwise well-informed practitioners — is treating probiotics as a category rather than as individual organisms. Lactobacillus rhamnosus GG has strong evidence for preventing antibiotic-associated diarrhoea and reducing rotavirus diarrhoea duration in children. That evidence does not extend to other Lactobacillus rhamnosus strains, and it certainly does not extend to Lactobacillus acidophilus or Bifidobacterium longum. Each strain is a different organism with a different ecological niche, different metabolic outputs, and different interactions with the host immune system. Treating them as interchangeable because they share a genus name is the equivalent of prescribing any antibiotic for any bacterial infection because antibiotics work on bacteria.
The Strain Specificity That Actually Matters
When Probiotics Make Things Worse — The SIBO Problem
In someone with established small intestinal bacterial overgrowth, standard Lactobacillus and Bifidobacterium probiotics can worsen symptoms significantly. These organisms ferment carbohydrates in the small intestine — exactly where SIBO is already producing excessive fermentation and gas. The person with bloating, brain fog, and distension following probiotics almost certainly has SIBO. Introducing more fermenting bacteria into an overpopulated small intestine is clinically counterproductive. This is one of the most common reasons people have negative experiences with probiotics — not because the probiotic is ineffective, but because it is contraindicated in their specific situation. Assess for SIBO before recommending standard Lactobacillus probiotics in anyone with significant small intestinal symptoms.
What the GI-MAP Tells You About Which Probiotics Are Needed
This is where the test-don’t-guess principle applies directly to probiotic selection. The GI-MAP quantifies key probiotic species — Lactobacillus species, Bifidobacterium species, and Akkermansia muciniphila in particular — giving a direct picture of which commensal bacteria are depleted and therefore which supplementation approach is most clinically relevant.
Low Lactobacillus species with normal Bifidobacterium suggests a different supplementation priority than the reverse. Very low Akkermansia suggests that barrier integrity is the primary concern and Akkermansia supplementation or prebiotic support for its growth (polyphenols and resistant starch are particularly effective) takes priority. Low secretory IgA alongside low commensals suggests that immune support for the gut mucosal layer — colostrum, immunoglobulins — should accompany probiotic restoration.
Without GI-MAP data, probiotic selection is guesswork — choosing products based on marketing, price, or the enthusiastic recommendation of someone whose gut ecology is nothing like yours. With GI-MAP data, the selection is targeted: these specific species are depleted, therefore these specific strains are the clinical priority.
The Timing and Sequencing That Determines Whether They Work
Even the right probiotic taken at the wrong time or in the wrong sequence produces poor results. The clinical sequencing matters:
During antibiotics: Saccharomyces boulardii is appropriate — it is not affected by antibiotics. Standard bacterial probiotics taken simultaneously with antibiotics are largely destroyed by the antibiotic. They are not useless — the ecological presence they maintain provides some benefit — but the effect is significantly reduced. Take bacterial probiotics as far as possible from the antibiotic dose in timing, or wait until the course is finished.
Immediately post-antibiotics: Spore-based Bacillus species first. Two to four weeks to re-establish the ecological conditions. Then introduce Lactobacillus and Bifidobacterium species. Then, once the ecology is re-establishing, introduce prebiotic fibre to feed the new residents.
After SIBO treatment: Same sequence as post-antibiotics. Do not introduce fermenting Lactobacillus species immediately after antimicrobials. The washout period matters — allow two to three weeks before introducing standard probiotics. Spore-based probiotics first.
For long-term maintenance: Diverse Lactobacillus and Bifidobacterium species alongside dietary diversity producing diverse prebiotic substrates. The probiotic supplement is a support to the ecology, not a replacement for the diet that sustains it.
Test before supplementing. GI-MAP identifies which species are depleted. This determines which strains are the clinical priority and eliminates the guesswork from selection.
Match strain to condition. Saccharomyces boulardii for antibiotic use, traveller’s diarrhoea, and Candida. Lactobacillus rhamnosus GG for acute diarrhoea and post-antibiotic restoration. Bifidobacterium longum for anxiety, sleep, and IBS with a stress component. Akkermansia for barrier integrity and metabolic health. Spore-based for post-antimicrobial ecological restoration.
Rule out SIBO first. Significant small intestinal symptoms with worsening on probiotics strongly suggests SIBO. Address SIBO before introducing fermenting probiotic species.
The diet does the work the probiotic cannot. A probiotic taken without dietary diversity providing the prebiotic substrate those bacteria need is a temporary visitor. The organisms introduced by supplementation are transient — they do not colonise permanently. What determines the long-term ecology is the diet that selects for specific species by feeding them. Probiotics are the intervention; diet is the maintenance.
The probiotic conversation in functional medicine has been dominated by the same generic approach that characterises mainstream supplement recommendations — take a broad-spectrum multi-strain product and hope something in it helps. The actual research on probiotics is far more specific, far more interesting, and far more clinically actionable than this approach suggests. The right strain, for the right condition, at the right time in the right sequence, selected on the basis of what the GI-MAP shows is actually depleted — this is what distinguishes clinical probiotic prescribing from wellness supplementation. The gap between those two things is the gap between results and expensive urine.